Evaxion A/S (NASDAQ:EVAX) versus Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head Survey

Taysha Gene Therapies (NASDAQ:TSHA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Taysha Gene Therapies and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Evaxion A/S	N/A	-61.43%	-34.23%

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Taysha Gene Therapies and Evaxion A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	147.74	-$109.00 million	($0.42)	-10.55
Evaxion A/S	$7.53 million	3.65	-$7.71 million	($1.21)	-2.52

Evaxion A/S has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Taysha Gene Therapies and Evaxion A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
Evaxion A/S	1	0	5	0	2.67

Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 188.24%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 260.66%. Given Evaxion A/S’s higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Taysha Gene Therapies.

Volatility & Risk

Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Summary

Taysha Gene Therapies beats Evaxion A/S on 9 of the 14 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.